Emerging therapies for urothelial cancer

César Serrano, Rafael Morales, Cristina Suárez, Isaac Núñez, Claudia Valverde, Jordi Rodón, Jordi Humbert, Olga Padrós, Joan Carles

    Research output: Contribution to journalReview articleResearchpeer-review

    9 Citations (Scopus)


    Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials. © 2011 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)311-317
    JournalCancer Treatment Reviews
    Issue number4
    Publication statusPublished - 1 Jun 2012


    • Anti-EGFR
    • Bladder cancer
    • Emerging treatments
    • Eribulin
    • MTOR inhibition
    • Nab-paclitaxel
    • PARP
    • Sorafenib
    • Sunitinib
    • Volasertib


    Dive into the research topics of 'Emerging therapies for urothelial cancer'. Together they form a unique fingerprint.

    Cite this